Lieber mal ´ne XOMA, als vom MediaMarkt die Oma !

XOMA Ltd. Royalties On CIMZIA Expected To Increase Due To FDA Approval For Moderate To Severe Rheumatoid Arthritis In Adults
Thursday, 14 May 2009 03:26pm EDT
XOMA Ltd. announced that its bacterial cell expression (BCE) technology licensee UCB S.A. has received FDA approval to market CIMZIA (certolizumab pegol), an anti tumor necrosis factor product, for the treatment of moderate to severe rheumatoid arthritis (RA) in adults. XOMA will receive royalty payments on sales of CIMZIA for this indication and will continue to receive royalties on sales of CIMZIA for the treatment of moderate to severe Crohn's disease, for which it was approved in April 2008.  

http://www.reuters.com/finance/stocks/...amp;timestamp=20090515110000  

XOMA Announces $10 Million Financing...

http://money.cnn.com/news/newsfeeds/articles/globenewswire/165537.htm  

hab auch noch ein paar nachgelegt...zu 0,678€  

sind ja wahnsinns-kauf-kurse

drys + xoma
Direkt antworten Mit Zitat antworten
drys



xoma
[IMG]http://de.advfn.com/...mp;s=N^XOMA&p=0&t=39&vol=1://[/IMG
Nach oben
Morgen geht wieder die Sonne auf.........oder

XOMA buy
18.05.2009 - 11:47

Rating-Update:

Los Angeles (aktiencheck.de AG) - Die Analystin Liana Moussatos von Wedbush Morgan Securities stuft die Aktie von XOMA (ISIN BMG9825R1079/ WKN 871239) weiterhin mit dem Rating "buy" ein. Das Kursziel werde unverändert bei 2 USD gesehen. (15.05.2009/ac/a/u) Analyse-Datum: 15.05.2009


Quelle: Finanzen.net

Posted by: Iron heart    Date: Monday, June 01, 2009 4:07:42 AM  
In reply to: None  Post # of 351    

Therapeutic Antibodies: Potential to Revolutionize Treatment of Autoimmune Diseases

* On Sunday May 31, 2009, 11:45 pm EDT

......
In the following brief excerpt from the 107 page report, the CEO of Xoma discuss the outlook for using therapeutic antibodies for the treatment of autoimmune diseases.

TWST: Please begin with a brief historical sketch of the company and a picture of the things you are doing at the present time.

Mr. Engle: We are a recognized leader in the discovery and development of therapeutic antibodies. Our lead product, XOMA 052, is a potentially revolutionary treatment for the inflammatory cause of many major diseases including Type II diabetes, cardiovascular disease and autoimmune diseases. In addition, XOMA receives revenues from: the licensing of its antibody technologies to over 50 companies; product royalties (LUCENTIS and CIMZIA); development collaborations with Takeda, Novartis and Schering-Plough; and biodefense contracts. Based in Berkeley, California, XOMA has 200 employees.Our lead product candidate, XOMA 052, is a proprietary antibody that regulates production of the cytokine called interleukin-1 or IL-1, which is the master cytokine in activating the inflammatory cascade. We recently received a US patent for XOMA 052, providing an important acknowledgement that it has properties that differentiate it from other agents that target IL-1. We recently completed enrollment in Phase I studies of XOMA 052 in Type II diabetes and plan to announce top-line results from the US trial in July. The trials evaluated a wide range of XOMA 052 doses, single and multiple dose regimens, and intravenous and subcutaneous routes of administration. Interim results presented last fall from the single dose IV trials demonstrated that XOMA 052 is well tolerated across all doses. Further, XOMA 052 showed evidence of biological activity, including reduced levels of glycosylated hemoglobin, increased insulin production and reduced levels of C-reactive protein, or CRP, compared to placebo. CRP is a well-established marker for the systemic inflammation associated with cardiovascular disease, one of the largest pharmaceutical markets. For this reason, we have begun to evaluate XOMA 052 for its potential cardiovascular benefits in addition to considering it for development in diabetes and autoimmune diseases. In addition to XOMA 052 and the other products in our proprietary pipeline, we have a business focused on collaborations with other companies using our broad antibody technologies, a business focused on biodefense funded by the US government, and a royalty-based business based on our pioneering position in developing antibodies for therapeutic uses. We currently receive royalties on sales of LUCENTIS from Genentech and CIMZIA from UCB.

TWST: Would you sketch out your strategic agenda for the next two to three years?

Mr. Engle: We are very focused on advancing the development of XOMA 052 for diabetes and cardiovascular disease because it is a revolutionary approach and has the greatest single potential for maximizing the return to shareholders. Discussions toward a corporate partnership for XOMA 052 are underway and we plan to finalize this partnership by year-end. We plan to advance XOMA 052 for other indications and continue bringing forward the other proprietary compounds we have in pre-clinical development. With the advancement of XOMA 052, establishment of a corporate partnership, advancement of our pre-clinical pipeline and our other businesses, we believe we have multiple opportunities to significantly grow shareholder value.

The Wall Street Transcript is a unique service for investors and industry researchers - providing fresh commentary and insight through verbatim interviews with CEOs and research analysts. This 107 page special issue is available by calling (212) 952-7433 or via The Wall Street Transcript Online .

The Wall Street Transcript does not endorse the views of any interviewees nor does it make stock recommendations.

For Information on subscribing to The Wall Street Transcript, please call 800/246-7673  

 

http://www.stoxline.com/quote.php?symbol=xoma  

lala  

was ist de heute passiert? wieso ist die so gestiegen? gabs da irgenwelche guten nachrichten?
 

hat nen klaren Vorteil

aber was muss ich lesen? bzw. wo?
 

..so sieht man sich wieder...lala :-)